1. GPCR/G Protein
  2. Prostaglandin Receptor

Latanoprost 

Cat. No.: HY-B0577 Purity: 96.81%
Data Sheet SDS Handling Instructions

Latanoprost is a selective agonist for the FP prostanoid receptor, is used as a powerful antiglaucoma agent.

For research use only. We do not sell to patients.
Latanoprost Chemical Structure

Latanoprost Chemical Structure

CAS No. : 130209-82-4

Size Price Stock Quantity
10 mM * 1 mL in DMSO $121 In-stock
5 mg $110 In-stock
10 mg $170 In-stock
25 mg $400 In-stock
50 mg $700 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Latanoprost is a selective agonist for the FP prostanoid receptor, is used as a powerful antiglaucoma agent.

In Vitro

Benzalkonium chloride latanoprost (BAK-latanoprost) and 0.02% BAK induce significant apoptosis in the apical layers that correlated with the significant decrease of cell viability. Preservative-free latanoprost (PF-latanoprost) slightly decreases cell viability and few apoptotic cells are found in the superficial layers, without reaching statistical significance compared with PBS[1]. Latanoprost (0.1 μM) significantly increases cell viability as compared with control. Meanwhile, 0.1 μM latanoprost results in the obvious promotion of neurite outgrowth similar to ciliary neurotrophic factor (CNTF) and simultaneously increases the levels of p-Akt and p-mTOR expression. Latanoprost can promote neurite outgrowth through an FP receptor-mediated modulation of the PI3K-Akt-mTOR signaling pathway[3]. Latanoprost (0.03 or 0.3 μg/mL) and bimatoprost increase MMP-9 activity by 75% ± 27% and 75% ± 24%, respectively, in human CBSM cells[4].

In Vivo

A single drop of latanoprost results in marked miosis, anterior bowing of the peripheral iris, narrowing of the iridocorneal angle, and shallowing of the anterior chamber of the beagle dog. Following latanoprost, the pupil diameter, ACA, and AOD (means) decreases 84%, 14%, and 16%, respectively[2].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01580254 University of Cantanzaro Intraocular Pressure (IOP)|Tear Break-Up Time June 2011 Phase 4
NCT00638742 Pfizer Glaucoma|Ocular Hypertension May 2008 Phase 1
NCT01430923 Aurolab Glaucoma, Open-Angle|Ocular Hypertension September 2011
NCT01180062 Daniel Moore|Pfizer|University of Kentucky Primary Open Angle Glaucoma (POAG)|Ocular Hypertension (OHT) January 2011 Phase 1
NCT00187577 University of California, San Francisco Alopecia Areata June 2005
NCT01721707 Adapt Produtos Oftalmológicos Ltda. Open Angle Glaucoma|Ocular Hypertension December 2012 Phase 3
NCT01225653 University of Aarhus|Aarhus University Hospital Diabetic Retinopathy November 2010 Phase 4
NCT00224289 Yale University|Pfizer Glaucoma March 2005 Phase 4
NCT00757835 Aristotle University Of Thessaloniki|Alcon Research Glaucoma May 2008 Phase 4
NCT00712400 Medical University of Vienna Ocular Physiology|Intraocular Pressure|Regional Blood Flow June 2005
NCT02792803 Dr. David Yan|Allergan|DBYAN Medicine Professional Corporation POAG|Primary Open Angle Glaucoma|Ocular Hypertension September 2015 Phase 4
NCT00856622 Pfizer Ocular Hypertension|Glaucoma|Open-Angle Glaucoma August 1997 Phase 3
NCT00579969 University of Nebraska Glaucoma December 2003 Phase 2
NCT01162603 Azienda Ospedaliera Spedali Civili di Brescia|Aristotle University Of Thessaloniki Primary Open Angle Glaucoma|Ocular Hypertension March 2011 Phase 4
NCT00906594 University of Sao Paulo Glaucoma September 2007 Phase 4
NCT02466399 Peregrine Ophthalmic Glaucoma July 2015 Phase 2
NCT02014142 Mati Therapeutics Inc. Ocular Hypertension|Open-Angle Glaucoma December 2013 Phase 2
NCT01896180 Alleanza Pharmaceuticals, Inc. Primary Open Angle Glaucoma|Ocular Hypertension|Elevated Intraocular Pressure July 2013 Phase 2
NCT01361841 Centre de recherche du Centre hospitalier universitaire de Sherbrooke Ocular Hypertension|Primary Glaucoma January 2009
NCT00855517 Mati Therapeutics Inc. Glaucoma|Ocular Hypertension March 2009 Phase 2
NCT01975714 Association for Innovation and Biomedical Research on Light and Image|European Vision Institute Clinical Research Network Glaucoma|Ocular Hypertension October 2013 Phase 4
NCT01527682 Azienda Ospedaliera Spedali Civili di Brescia Childhood Glaucoma July 2009 Phase 2
NCT02822742 Santen Pharmaceutical Co., Ltd. Primary Open Angle Glaucoma or Ocular Hypertension July 2016 Phase 3
NCT02350023 Postgraduate Institute of Medical Education and Research Alopecia Areata September 2014 Phase 4
NCT01426464 Nanduri, Padma, M.D., FACS Glaucoma September 2011 Phase 2
NCT01779284 Aristotle University Of Thessaloniki Glaucoma January 2012 Phase 4
NCT00647101 Pfizer Glaucoma, Open-Angle|Ocular Hypertension December 2003 Phase 4
NCT01448837 Aristotle University Of Thessaloniki Glaucoma April 2010 Phase 4
NCT02981446 Santen Pharmaceutical Co., Ltd. Open Angle Glaucoma or Ocular Hypertension November 2016 Phase 3
NCT00219596 Pfizer Glaucoma, Open Angle|Ocular Hypertension June 2005 Phase 3
NCT00847483 Pfizer Glaucoma|Ocular Hypertension January 2002 Phase 4
NCT01973114 Synphora AB Menière's Disease October 2013 Phase 2
NCT01379144 Pfizer Primary Open Angle Glaucoma|Ocular Hypertension January 2003 Phase 2
NCT01229982 Mati Therapeutics Inc. Ocular Hypertension|Open Angle Glaucoma October 2010 Phase 2
NCT02585375 Medical University of Vienna Glaucoma|Ocular Hypertension April 2015 Phase 4
NCT00800267 Pfizer Ocular Hypertension|Glaucoma July 1997 Phase 3
NCT01987323 Singapore Eye Research Institute Ocular Hypertension January 2013 Phase 1|Phase 2
NCT02531152 Sanofi Open Angle Glaucoma -Ocular Hypertension September 2015 Phase 1
NCT00706927 Medical University of Vienna Retina|Ocular Physiology January 2006
NCT01481051 Mati Therapeutics Inc. Glaucoma|Ocular Hypertension (OH) November 2011 Phase 2
NCT01042665 University of Miami|Pfizer Glaucoma February 2006
NCT00941525 Aristotle University Of Thessaloniki Open Angle Glaucoma|Ocular Hypertension September 2009 Phase 4
NCT02154217 University of Milan Glaucoma Phase 3
NCT00541242 Allergan Ocular Hypertension|Glaucoma December 2007 Phase 4
NCT01481077 Mati Therapeutics Inc. Glaucoma|Ocular Hypertension (OH) November 2011 Phase 2
NCT01151904 Allergan Glaucoma, Angle-Closure November 2009 Phase 4
NCT00347841 Innovative Medical Glaucoma Phase 4
NCT02829996 Inotek Pharmaceuticals Corporation Primary Open-Angle Glaucoma (POAG)|Ocular Hypertension (OHT) August 19, 2016 Phase 2
NCT00820300 Mati Therapeutics Inc. Glaucoma|Ocular Hypertension January 2009 Phase 2
NCT01731002 Aerie Pharmaceuticals Ocular Hypertension|Open Angle Glaucoma November 2012 Phase 2
NCT00845299 Mati Therapeutics Inc. Glaucoma|Ocular Hypertension January 2009 Phase 2
NCT00567788 Singapore National Eye Centre|Allergan Glaucoma, Angle-Closure July 2006
NCT00441883 Bausch & Lomb Incorporated|NicOx Inc. Primary Open Angle Glaucoma|Ocular Hypertension|Pigmentary Glaucoma|Pseudoexfoliative Glaucoma March 2007 Phase 2
NCT01917383 Inotek Pharmaceuticals Corporation Primary Open-Angle Glaucoma (POAG)|Ocular Hypertension (OHT) August 2013 Phase 2
NCT02047630 CHU de Quebec-Universite Laval Primary Open Angle Glaucoma|Ocular Hypertension January 2014 Phase 4
NCT02129673 ViSci Ltd. Open Angle Glaucoma|Ocular Hypertension May 2014 Phase 1|Phase 2
NCT00051142 Alcon Research Glaucoma, Open-Angle|Ocular Hypertension February 2001 Phase 3
NCT00872651 Alcon Research Open-angle Glaucoma|Ocular Hypertension January 2010 Phase 3
NCT00397241 Aristotle University Of Thessaloniki Open-angle Glaucoma September 2006 Phase 4
NCT00051181 Alcon Research Glaucoma, Angle-Closure|Ocular Hypertension January 2000 Phase 3
NCT01243567 Allergan Glaucoma, Open-Angle June 2010 Phase 4
NCT00804115 The New York Eye & Ear Infirmary|Pfizer Exfoliation Syndrome|Glaucoma|Ocular Hypertension August 2000
NCT00402493 Philadelphia Eye Associates|Pfizer Glaucoma|Ocular Hypertension December 2006
NCT00821002 Mati Therapeutics Inc.|QLT Inc. Open-Angle Glaucoma|Ocular Hypertension January 2009 Phase 2
NCT00716859 Pfizer Glaucoma July 2008 Phase 3
NCT01223378 Bausch & Lomb Incorporated Intraocular Pressure December 2010 Phase 2
NCT01302249 Aerie Pharmaceuticals Glaucoma|Ocular Hypertension February 2011 Phase 2
NCT00934089 Pfizer Glaucoma, Open-Angle|Ocular Hypertension January 2010 Phase 2
NCT01037036 Mati Therapeutics Inc.|QLT Inc. Ocular Hypertension|Open-Angle Glaucoma December 2009 Phase 2
NCT00348400 Innovative Medical Glaucoma Phase 4
NCT00440141 Allergan Glaucoma|Ocular Hypertension July 2006 Phase 4
NCT00705757 Summa Health System Glaucoma|Application Site Pigmentation Changes March 2008 Phase 4
NCT01254370 Santen SAS Glaucoma|Ocular Hypertension|Ocular Surface Disease November 2010 Phase 2
NCT00811564 Allergan Glaucoma|Ocular Hypertension December 2008 Phase 4
NCT00304785 Pharmaceutical Research Network Open-Angle Glaucoma|Ocular Hypertension May 2005 Phase 4
NCT00846989 Novartis Pharmaceuticals|Novartis Glaucoma|Ocular Hypertension January 2009 Phase 1|Phase 2
NCT01084902 Peking University First Hospital Ocular Hypertension February 2010
NCT01060579 Aerie Pharmaceuticals Glaucoma February 2010 Phase 2
NCT01525173 Allergan Glaucoma|Ocular Hypertension January 2012 Phase 4
NCT01433900 Paolo Fogagnolo|University of Milan Glaucoma May 2012 Phase 3
NCT02108288 Otsuka Pharmaceutical Co., Ltd. Glaucoma|Ocular Hypertension April 2014 Phase 1
NCT00716742 Allergan Open-Angle Glaucoma|Ocular Hypertension September 2004
NCT00308945 University Hospital, Basel, Switzerland Open-Angle Glaucoma November 2003 Phase 4
NCT02623738 Santen Pharmaceutical Co., Ltd. Primary Open Angle Glaucoma|Ocular Hypertension November 2015 Phase 2|Phase 3
NCT01677507 University of Michigan|University of Nebraska|Mayo Clinic|National Eye Institute (NEI) Glaucoma|Healthy August 2012 Phase 4
NCT01639807 Aurolab Glaucoma October 2011
NCT02656979 Umeå University Glaucoma December 2013
NCT01315574 Massachusetts Eye and Ear Infirmary|Alcon Research Glaucoma February 2011 Phase 4
NCT00708422 Alcon Research Glaucoma|Ocular Hypertension July 2008 Phase 4
NCT03067415 Chong Kun Dang Pharmaceutical Glaucoma, Primary Open Angle|Ocular Hypertension March 30, 2017 Phase 2
NCT00595101 Bausch & Lomb Incorporated Primary Open Angle Glaucoma|Ocular Hypertension December 2007 Phase 2
NCT00527592 Alcon Research Open-Angle Glaucoma|Ocular Hypertension May 2007 Phase 4
NCT00230763 Pfizer Glaucoma, Primary Open Angle (POAG)|Ocular Hypertension September 2005 Phase 3
NCT01318252 Alcon Research Open-angle Glaucoma (OAG)|Ocular Hypertension (OHT) June 2011 Phase 2
NCT02522039 Glostrup University Hospital, Copenhagen Drug Effect (Glaucoma Drugs) May 2014
NCT01253902 Allergan Glaucoma, Open-Angle|Ocular Hypertension December 2010 Phase 4
NCT02083289 Ono Pharmaceutical Co. Ltd Ocular Hypertension|Open Angle-glaucoma May 2014 Phase 2
NCT00140062 Pfizer Ocular Hypertension|Glaucoma, Open-Angle February 2002 Phase 4
NCT02105272 Otsuka Pharmaceutical Co., Ltd. Glaucoma|Ocular Hypertension April 2014 Phase 3
NCT00650702 Mati Therapeutics Inc. Glaucoma|Ocular Hypertension March 2008 Phase 2
NCT01175902 The Catholic University of Korea|Seoul St. Mary's Hospital Normal Tension Glaucoma March 2011
NCT02622334 Hoffmann-La Roche Glaucoma December 31, 2015 Phase 1
NCT01868126 Santen Inc. Open-angle Glaucoma or Ocular Hypertension May 2013 Phase 2
NCT00572455 Pfizer Primary Open Angle Glaucoma|Ocular Hypertension December 2007 Phase 2
NCT00761319 Alcon Research Open-angle Glaucoma|Ocular Hypertension October 2008 Phase 3
NCT00798759 Alcon Research Open-angle Glaucoma|Ocular Hypertension December 2008 Phase 4
NCT02674854 Aerie Pharmaceuticals Open-angle Glaucoma|Ocular Hypertension February 2016 Phase 3
NCT02558400 Aerie Pharmaceuticals Open-angle Glaucoma|Ocular Hypertension September 2015 Phase 3
NCT00759941 Alcon Research Glaucoma October 2007 Phase 4
NCT00913029 Glaukos Corporation Eye Diseases|Glaucoma, Open-Angle|Glaucoma May 2009 Phase 4
NCT01410188 Acucela Inc.|Otsuka Pharmaceutical Co., Ltd. Primary Open-angle Glaucoma|Ocular Hypertension September 2011 Phase 1|Phase 2
NCT00735449 Allergan Glaucoma|Ocular Hypertension July 2008 Phase 4
NCT00690794 Alcon Research Open-angle Glaucoma|Ocular Hypertension July 2008 Phase 3
NCT00330577 Aristotle University Of Thessaloniki Primary Open Angle Glaucoma|Ocular Hypertension April 2006 Phase 4
NCT00311389 Alcon Research Glaucoma, Open-angle|Ocular Hypertension January 2003 Phase 3
NCT00868894 Santen Inc. Open-Angle Glaucoma|Ocular Hypertension March 2009 Phase 1|Phase 2
NCT01201551 University Hospital, Basel, Switzerland Primary Vascular Dysregulation June 2011
NCT00539526 Allergan Open Angle Glaucoma|Ocular Hypertension September 2007 Phase 4
NCT00892762 Alcon Research Open Angle Glaucoma|Ocular Hypertension June 2009 Phase 3
NCT00273429 Pharmaceutical Research Network Open-Angle Glaucoma|Ocular Hypertension April 2005 Phase 4
NCT01191008 Pfizer Glaucoma|Ocular Hypertension October 2010
NCT03216902 Santen Inc. Open-angle Glaucoma, Ocular Hypertension July 2017 Phase 2
NCT00972426 Taiwan Otsuka Pharm. Co., Ltd Glaucoma October 2009 Phase 4
NCT00761709 Alcon Research Open-Angle Glaucoma|Ocular Hypertension July 2009 Phase 2
NCT01978015 University of Campinas, Brazil Uveitis, Anterior|Cystoid Macular Edema October 2011 Phase 4
NCT02057575 Aerie Pharmaceuticals Open Angle Glaucoma|Ocular Hypertension January 2014 Phase 2
NCT00619034 University of Aarhus Diabetic Retinopathy September 2007
NCT00650338 Santen Inc. Open-Angle Glaucoma|Ocular Hypertension March 2008 Phase 2
NCT00051155 Alcon Research Glaucoma, Open-Angle|Ocular Hypertension January 2001 Phase 3
NCT00815373 Meir Medical Center Open-Angle Glaucoma|Ocular Hypertension December 2008
NCT00329095 Robin, Alan L., M.D. Glaucoma|Ocular Hypertension December 2005 Phase 4
NCT00620256 Alcon Research Open-Angle Glaucoma|Ocular Hypertension November 2007 Phase 2
NCT00887029 Ophthalmic Consultants Centres, Canada|Alcon Research Open-Angle Glaucoma|Ocular Hypertension January 2009 Phase 4
NCT02179008 Santen Inc. Open-angle Glaucoma|Ocular Hypertension June 2014 Phase 2
NCT00069706 Alcon Research Open-angle Glaucoma|Ocular Hypertension July 2003 Phase 2
NCT01157364 Allergan Open-Angle Glaucoma|Ocular Hypertension August 2010 Phase 1|Phase 2
NCT00287521 Alcon Research Open-angle Glaucoma|Ocular Hypertension November 2005 Phase 2
NCT01655758 University of Parma Ocular Hypertension January 2002 Phase 4
NCT00273481 Pharmaceutical Research Network Open-Angle Glaucoma|Ocular Hypertension September 2005 Phase 4
NCT00293800 Alcon Research Open-Angle Glaucoma|Ocular Hypertension July 2004 Phase 3
NCT00293787 Alcon Research Open-angle Glaucoma|Ocular Hypertension June 2004 Phase 3
NCT02390284 University of Miami|National Eye Institute (NEI) Glaucoma September 2014 Phase 3
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.3117 mL 11.5583 mL 23.1166 mL
5 mM 0.4623 mL 2.3117 mL 4.6233 mL
10 mM 0.2312 mL 1.1558 mL 2.3117 mL
Cell Assay
[1]

Latanoprost is dissolved in PBS.

Cellular viability is evaluated in duplicate at 24 hours with the MTT assay. The 3D-HCEs are transferred to 24-well plates containing 300 μL of MTT solution diluted at 0.5 mg/mL in the culture medium, and 300 μL of the same MTT solution is applied on the apical surface of the 3D-HCEs. Reconstituted tissues are incubated for 3 hours at 37°C. Then they are transferred to 24-well plates containing 750-μL isopropanol, and 750-μL isopropanol is added to the apical surface of the 3D-HCEs. The plates are agitated for 2 hours at room temperature before reading the optical density (OD) at 570 nm versus OD 690 nm. The results are expressed as percentages of cell viability (mean ± SD) compared with the negative control (PBS). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

432.59

Formula

C₂₆H₄₀O₅

CAS No.

130209-82-4

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Latanoprost
Cat. No.:
HY-B0577
Quantity: